Tesamorelin vs CJC-1295 + Ipamorelin

Tesamorelin wins for targeted visceral fat and hepatic fat loss, maximum MRI-verified VAT reduction, and specific NAFLD/metabolic-cleanup cycles. Mechanistically unique for reducing 'GH gut' and reversing liver fat, with clinical data to back it. Dosing is low-frequency and liver-specific results are predictable.

CJC-1295 + Ipamorelin wins for overall tissue quality, recovery, sleep, ease of sourcing, and a gentler side effect profile for longer cycles. Delivers systemic, physiologic GH/IGF-1 pulses with stacking synergy, minimal cortisol/prolactin sides, and more applications (sleep, connective tissue, skin). Easier to source and dose-titrate for lifestyle/looksmaxxing scenarios.

Pick Tesamorelin if:

• You want maximal, proven reduction of visceral/abdominal fat (VAT) as confirmed in clinical imaging
• Trying to reverse "GH gut" or AAS/HGH-induced abdominal distension
• Need to address NAFLD, elevated liver fat, or metabolic syndrome in a looksmaxxing context
• Want a protocol with simple, once-daily SC dosing and a capped, time-limited run (20–26 weeks)
• Already have a solid recovery stack and want visceral fat mobilization as the primary endpoint

Pick CJC-1295 + Ipamorelin if:

• Seeking global improvement in sleep, recovery, skin quality, and mild body recomposition
• Want a GH-axis boost with the flexibility to stack alongside AAS, BPC-157, or for general anti-aging/longevity goals
• Are sensitive to glucose or insulin resistance concerns and want a safer long-term profile
• Prefer a protocol that's easier to obtain, dose, and titrate — and with less potent (but gentler) results
• Looking to run multiple moderate cycles per year rather than a single high-impact VAT reduction protocol